All patients | R5 subgroup patients | X4 subgroup patients | p | |
---|---|---|---|---|
Number | 219 | 146 | 73 | ns |
Male (n) | 173 | 118 | 55 | ns |
Italian (n) | 180 | 114 | 66 | ns |
Agea (years) | 41 (19–79) | 40 (19–74) | 43 (21–79) | p= 0.0332 |
Risk b | ||||
Heterosexual (n) | 91 | 60 | 31 | ns |
MSM (n) | 67 | 47 | 20 | ns |
Drug user (n) | 18 | 11 | 7 | ns |
Missing (n) | 43 | 28 | 15 | ns |
Subtype-B (n) | 171 | 113 | 56 | ns |
Primarycn (%) | 29 (13.2%) | 21 (14.3%) | 8 (11%) | Ns |
T0 CD4 cells/mm3a | 260 (0–1090) | 284 (0–810) | 201 (7–1090) | p= 0.0216 |
T0 CD4%a | 16 (0–39) | 17 (0–37) | 13 (1–39) | ns |
T0 HIV RNAa copies/ml | 101836 (412–1x107) | 101836 (412–1x107) | 1000182 (547–6258236) | ns |
T0 HIV DNAa, d | 1198 (33–70123) | 1185 (70–18856) | 1297 (33–70123) | ns |
T1 CD4 cells/mm3a | 560 (54–1330) | 580 (54–1306) | 485 (96–1330) | ns |
T1 CD4%a | 28.9 (3.4–55.2) | 29.9 (3.4–55,2) | 26 (5–51.9) | ns |
T1 HIV RNA<2,5 copies/ml n (%) | 83 (37.9%) | 62 (42.4%) | 21 (28.7%) | ns |
T1 HIV DNAa, d | 107 (5–892) | 105 (5–892) | 110 (5–740) | ns |